title: [Selecting variants of drug treatment of non-complicated duodenal ulcer (based on a study of results of Rabeprazole efficiency)].
abstract: This article presents considerations currently under discussion about the probability of HP participation in the ulcer causation as well as information about Rabeprazole efficiency for anti-helicobacter therapy of non-complicated duodenal ulcer (as a result of 7-day anti-helicobacter therapy, the healing of duodenal bulbs was recorded in 82.6% of cases; HP eradication was recorded in 86.9% of cases 4 weeks after the termination of the treatment) based on the analysis of scientific literature data and personal experience. Considerations related to the conduction of a possible study in the field of ulcer therapy that is not associated with Helicobacter pylori are presented.
authors.forename: Iu B
authors.initials: IuB
authors.lastname: Vasil'ev
mesh_terms: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000897:Anti-Ulcer Agents / Q000627:therapeutic use*; D001562:Benzimidazoles / Q000627:therapeutic use*; D004381:Duodenal Ulcer / Q000188:drug therapy* / Q000382:microbiology; D005260:Female; D016481:Helicobacter Infections / Q000150:complications / Q000188:drug therapy*; D016480:Helicobacter pylori / Q000187:drug effects*; D006801:Humans; D008297:Male; D009853:Omeprazole / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D064750:Rabeprazole
chemical_list: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000897:Anti-Ulcer Agents; D001562:Benzimidazoles; D064750:Rabeprazole; D009853:Omeprazole